^
    Back
    Association details:
    Biomarker:PD-1 overexpression
    Cancer:Melanoma
    Drug:Opdivo (nivolumab) (PD1 inhibitor) +
    Yervoy (ipilimumab) (CTLA4 inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    New
    Source:
    CIMT 2021
    Title:

    Soluble immune checkpoints and T-cell subsets in blood as biomarkers for resistance to immunotherapy in melanoma patients

    Published date:
    05/07/2021
    Excerpt:
    ...resistance to ipilimumab plus nivolumab (n=42) was associated with high levels of sPD1 (DCR: p=0.019, PFS: p=0.046; ROC cut-off > 167 pg/ml)...soluble immune checkpoints characterized checkpoint inhibitor-resistant melanoma.